Inidascamine

Inidascamine
Clinical data
Other names	RL-007; RL007; FSV7-007
Routes of; administration	Oral
Identifiers
	IUPAC name (2R,3S)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-ylpropan-1-one;
CAS Number	903884-71-9;
PubChem CID	11535990;
ChemSpider	9710771;
UNII	3LW01V88B7;
ChEMBL	ChEMBL5095258;
CompTox Dashboard (EPA)	DTXSID90238113 ;
Chemical and physical data
Formula	C12H17N3O2
Molar mass	235.287 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CCN(C1)C(=O)[C@@H]([C@H](C2=CC=NC=C2)O)N;
	InChI InChI=1S/C12H17N3O2/c13-10(12(17)15-7-1-2-8-15)11(16)9-3-5-14-6-4-9/h3-6,10-11,16H,1-2,7-8,13H2/t10-,11+/m1/s1; Key:GRZMKKUGHIECFK-MNOVXSKESA-N;

Inidascamine (INNTooltip International Nonproprietary Name; developmental code names RL-007, FSV7-007) is an experimental drug which is under development for the treatment of cognitive impairment associated with schizophrenia (CIAS). It is taken orally. The drug is said to act on the cholinergic, NMDA, and GABA_B receptor systems. Inidascamine is being developed by Recognify Life Sciences and atai Life Sciences. It was discovered via screening of compounds for effects on synaptic plasticity and cognition. The drug shows structural similarities to phenethylamines and amphetamines.

Clinical data

Other names	RL-007; RL007; FSV7-007
Routes of administration	Oral
Identifiers
IUPAC name (2R,3S)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-ylpropan-1-one
CAS Number	903884-71-9
PubChem CID	11535990
ChemSpider	9710771
UNII	3LW01V88B7
ChEMBL	ChEMBL5095258
CompTox Dashboard (EPA)	DTXSID90238113
Chemical and physical data
Formula	C₁₂H₁₇N₃O₂
Molar mass	235.287 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES C1CCN(C1)C(=O)[C@@H]([C@H](C2=CC=NC=C2)O)N
InChI InChI=1S/C12H17N3O2/c13-10(12(17)15-7-1-2-8-15)11(16)9-3-5-14-6-4-9/h3-6,10-11,16H,1-2,7-8,13H2/t10-,11+/m1/s1 Key:GRZMKKUGHIECFK-MNOVXSKESA-N